ArticleDrug safety2009
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
Article in Drug safety, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Bisphosphonates and their influence on fracture healing: a systematic review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Pooled it
- Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.The Journal of bone and joint surgery. American volume · 2013Pooled it
- A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Pooled it
- Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Trial
- Risk factors for atypical femur fractures with and without bisphosphonate treatment: a national nested case-control study.JBMR plus · 2026Article
- Patient-reported effectiveness and safety of Pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children.Rheumatology international · 2022Article
- Fracture Risk Following an Atypical Femoral Fracture.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Increased rate of reoperation in atypical femoral fractures is related to patient characteristics and not fracture type. A nationwide cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Article
- Beneficial effects of Lactobacillus reuteri 6475 on bone density in male mice is dependent on lymphocytes.Scientific reports · 2019Article
- Bisphosphonate associated femoral stress fracture distal to an orthopaedic implant: They are predictable!Journal of clinical orthopaedics and trauma · 2019Article
- Spontaneous Insufficiency Fractures.The journal of nutrition, health & aging · 2019Article
- Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis.Journal of bone metabolism · 2018Review
- Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure.The American journal of gastroenterology · 2017Article
- Risk of atypical femoral fracture during and after bisphosphonate use.Acta orthopaedica · 2015Article
- Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails.Clinical orthopaedics and related research · 2014Article
- Long term bisphosphonate therapy & atypical femoral fractures: a word of caution.The Indian journal of medical research · 2014Article
- Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature.The Indian journal of medical research · 2014Review
- Atypical femoral fractures, bisphosphonates, and mechanical stress.Current osteoporosis reports · 2014Article
- Histology of 8 atypical femoral fractures: remodeling but no healing.Acta orthopaedica · 2014Article
- Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Canadian family physician Medecin de famille canadien · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBisphosphonates are effective and well tolerated anti-resorptive drugs used for the treatment of osteoporosis. However, some concerns about their potential long-term negative effects are emerging.
objectiveWe report a series of patients with a history of bisphosphonate treatment admitted to our institution with a low-energy subtrochanteric fracture. PATIENTS AND
methodsEight patients fulfilling these two criteria within the last 2 years were included in our retrospective analysis. All cases were reported to the Swiss National Pharmacovigilance Centre.
resultsAll patients presented with a typical radiological pattern consisting of a cortical thickening at the lateral femoral subtrochanteric cortex with a horizontal fracture line originating precisely at this level. Four patients eventually developed a stress fracture or complete fracture of the contralateral femur. Two patients demonstrated delayed healing of their fracture. Five patients had been on alendronate therapy for a period ranging from 16 months to 8 years, two had been on ibandronate for 4 months and 1 year, respectively, after changing from alendronate, and one patient had been on pamidronate until 1 year before the fracture occurred. Seven patients were also receiving long-term proton pump inhibitor (PPI) treatment which could have contributed to the increased risk of fracture. Four patients were receiving both PPI and long-term corticosteroid treatment. The hypothesis of a negative pharmacodynamic interaction between bisphosphonates, PPIs and corticosteroids which could lead to a decrease in bone strength after long-term use needs further investigation.
conclusionPrescribers should be aware of the possibility of these rare adverse reactions and the prolonged use of bisphosphonates should be reconsidered until long-term robust safety data are available.
Indexed as
Identifiers
19670917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.